Your browser doesn't support javascript.
loading
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland, S L; van Eerden, R A G; Westerdijk, K; Meertens, M; Koolen, S L W; Moes, D J A R; de Vries, N; Rosing, H; Otten, H; Vulink, A J E; Desar, I M E; Imholz, A L T; Gelderblom, H; van Erp, N P; Beijnen, J H; Mathijssen, R H J; Huitema, A D R; Steeghs, N.
Afiliación
  • Groenland SL; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: s.groenland@nki.nl.
  • van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Westerdijk K; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Meertens M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Moes DJAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Otten H; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
  • Vulink AJE; Department of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands.
  • Desar IME; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Imholz ALT; Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • van Erp NP; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrech
  • Steeghs N; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: n.steeghs@nki.nl.
Ann Oncol ; 33(10): 1071-1082, 2022 10.
Article en En | MEDLINE | ID: mdl-35777707
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monitoreo de Drogas / Oncología Médica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monitoreo de Drogas / Oncología Médica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article